Today’s Top Three in Pharma 012109

Will the Feds soon decide on drugs based on cost/effectiveness calculations? “They claim that they don’t want this to morph into a British-style agency that restricts access to medical products based on narrow cost criteria, but provisions tucked into the fiscal stimulus bill betray their real intentions…”

Teva and Lonza team up to go after biosimilar drug market. The two companies said on Tuesday they had formed a strategic partnership to become a leading global provider of biosimilars, or generic versions of biotechnology drugs.

A list of some promising new drug candidates for 2009, from the Pharma’s Cutting Edge blog. Some interesting stuff in the various pipelines…

—––

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Impactiviti is a pharma consultancy focused on helping pharma/biotech/medical devices companies identify optimal vendors for training/marketing needs.